This post was originally published on this site

Clear Harbor Asset Management LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 13.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,380 shares of the medical research company’s stock after selling 957 shares during the period. Clear Harbor Asset Management LLC’s holdings in Amgen were worth $1,467,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp raised its holdings in shares of Amgen by 19.1% in the third quarter. State Street Corp now owns 31,278,999 shares of the medical research company’s stock valued at $7,949,870,000 after purchasing an additional 5,016,641 shares during the last quarter. Morgan Stanley raised its holdings in shares of Amgen by 7.0% in the third quarter. Morgan Stanley now owns 8,565,891 shares of the medical research company’s stock valued at $2,177,107,000 after purchasing an additional 561,293 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Amgen by 2.5% in the third quarter. Nuveen Asset Management LLC now owns 3,997,342 shares of the medical research company’s stock valued at $1,015,964,000 after purchasing an additional 95,701 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of Amgen by 2.5% in the fourth quarter. California Public Employees Retirement System now owns 2,006,524 shares of the medical research company’s stock valued at $461,340,000 after purchasing an additional 49,664 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of Amgen by 4.9% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 1,324,190 shares of the medical research company’s stock valued at $304,470,000 after purchasing an additional 61,831 shares during the last quarter. Institutional investors own 75.23% of the company’s stock.

AMGN has been the topic of a number of recent analyst reports. Piper Sandler lowered their target price on shares of Amgen from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, February 3rd. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Sunday, December 27th. BMO Capital Markets lowered their target price on shares of Amgen from $308.00 to $304.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Cantor Fitzgerald boosted their target price on shares of Amgen from $280.00 to $295.00 and gave the stock an “overweight” rating in a report on Wednesday, February 3rd. Finally, Mizuho lowered their target price on shares of Amgen from $260.00 to $215.00 and set a “neutral” rating on the stock in a report on Monday, November 2nd. Eleven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $255.39.

In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $238.40, for a total transaction of $238,400.00. Following the transaction, the director now directly owns 16,805 shares in the company, valued at approximately $4,006,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan P. Graham sold 11,110 shares of the stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $236.51, for a total value of $2,627,626.10. The disclosure for this sale can be found here. Insiders have sold a total of 13,360 shares of company stock valued at $3,161,514 in the last three months. Insiders own 0.36% of the company’s stock.

Shares of Amgen stock opened at $238.46 on Thursday. The firm has a 50-day moving average of $238.25 and a 200-day moving average of $237.43. The stock has a market cap of $138.82 billion, a PE ratio of 19.23, a PEG ratio of 1.90 and a beta of 0.76. Amgen Inc. has a 52-week low of $177.05 and a 52-week high of $276.69. The company has a debt-to-equity ratio of 3.12, a quick ratio of 1.88 and a current ratio of 2.28.

Amgen (NASDAQ:AMGN) last issued its earnings results on Monday, February 1st. The medical research company reported $3.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.39 by $0.42. The firm had revenue of $6.63 billion during the quarter, compared to the consensus estimate of $6.57 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.64 earnings per share. Equities research analysts predict that Amgen Inc. will post 16.15 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, March 8th. Shareholders of record on Monday, February 15th will be given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date is Thursday, February 11th. This is an increase from Amgen’s previous quarterly dividend of $1.60. Amgen’s dividend payout ratio is currently 43.18%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.

Further Reading: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.